Page last updated: 2024-09-03

marimastat and Blood Diseases

marimastat has been researched along with Blood Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG	1

Trials

1 trial(s) available for marimastat and Blood Diseases

Article	Year
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-01, Volume: 11, Issue:9 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Nausea; Paclitaxel; Treatment Outcome	2005

Article

Year

Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-01, Volume: 11, Issue:9

Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Nausea; Paclitaxel; Treatment Outcome

2005